The Safety of Tenofovir Disoproxil Fumarate Taken With Other Anti-HIV Drugs to Treat HIV-Infected Patients
NCT ID: NCT00007436
Last Updated: 2005-06-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tenofovir disoproxil fumarate
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have completed another study on tenofovir DF without toxicity.
* Are willing to use intrauterine or effective barrier methods of birth control, both men and women, during the study and for 30 days following tenofovir DF treatment.
Exclusion Criteria
* Are taking drugs that may damage the kidney (nephrotoxic) including aminoglycoside antibiotics, amphotericin B, cidofovir, cisplatin, foscarnet, IV pentamidine, vancomycin, and oral or IV ganciclovir.
* Are taking agents that affect kidney function, such as probenecid.
* Are receiving systemic chemotherapy.
* Are taking systemic corticosteroids.
* Are taking experimental drugs except those that are approved by Gilead.
* Are currently participating in the GS-99-908 or GS-00-912 (expanded access) studies.
* Are pregnant or breast-feeding.
0 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gilead Sciences
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
East Bay AIDS Ctr
Berkeley, California, United States
Tower ID Med Associates
Los Angeles, California, United States
Pacific Horizons Med Group
San Francisco, California, United States
Harbor - UCLA Med Ctr
Torrance, California, United States
Univ of Colorado / Health Science Ctr
Denver, Colorado, United States
Physicans Home Service
Washington D.C., District of Columbia, United States
Steinhart Medical Associates
Miami, Florida, United States
Dr Gerald Pierone Jr
Vero Beach, Florida, United States
Northstar Med Clinic
Chicago, Illinois, United States
CRI New England
Brookline, Massachusetts, United States
Univ of Minnesota
Minneapolis, Minnesota, United States
Univ of Rochester Med Ctr
Rochester, New York, United States
Research & Education Group
Portland, Oregon, United States
Hershey Med Ctr
Hershey, Pennsylvania, United States
Anderson Clinical Research
Pittsburgh, Pennsylvania, United States
Roger Williams Med Ctr
Providence, Rhode Island, United States
Southwest Infectious Diseases Associates
Dallas, Texas, United States
Thomas Street Clinic
Houston, Texas, United States
Dr Philip C Craven
Tacoma, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GS-99-910
Identifier Type: -
Identifier Source: secondary_id
283F
Identifier Type: -
Identifier Source: org_study_id